AIDS
Review of HIV Tests
When you need to know quickly if your patient has contracted HIV, these options can provide a faster result.
JULY 4, 2025
State of the ART: HIV Management in 2025
Earlier initiation of ART and better medication options have resulted in a narrowing in the mortality gap between ...
JULY 3, 2025
Key Takeaways for PrEP, HIV Treatment and Other Infectious Diseases
CROI 2025 highlighted promising therapeutic modalities for HIV treatment and prevention.
JULY 3, 2025
Histoplasmosis Screening May Decrease Hospitalization, Mortality Among Those With HIV
Histoplasmosis screening using a urinary antigen detection test in people living with HIV can help diagnose this ...
JULY 3, 2025
HIV Research at a Crossroads: Defunding Is Not the Way Through
Today HIV research is at a crossroads, but defunding will ensure that it is not the Americans who will travel down ...
JUNE 29, 2025
Cabenuva Proves Effective in Practice
Adherence to daily antiretroviral therapy (ART) can be challenging for some people with HIV.
JUNE 28, 2025
Dual-Threshold For Beta-D-Glucan May Be a More Nuanced Approach
A more nuanced, dual-threshold approach can improve the use of a noninvasive assay for Pneumocystis jirovecii ...
JUNE 28, 2025
Crushing/Dissolving HIV Medication Effective for Hospitalized Patients
Providing dissolved or crushed Biktarvy through an enteral tube can achieve viral suppression and may be a good ...
JUNE 27, 2025
HIV Prevention: Considerations for Adolescents and Young Adults
During the adolescent and young adult years, people are faced with significant physical and developmental changes ...
APRIL 30, 2025
CROI Chair Calls Disruption of HIV Services ‘Cataclysmic and Cruel’
CROI 2025 is taking place during a tumultuous period for the scientific community here and abroad, according to ...
MARCH 10, 2025
Biktarvy’s Benefits Extend in Older Adults With HIV
Five-year follow-up data from the triple combination HIV therapy showed high rates of disease suppression and ...
FEBRUARY 20, 2025
Twice-Yearly Lenacapavir 100% Effective in Preventing HIV Among Cisgender Women
An interim analysis of PURPOSE 1 found twice-yearly lenacapavir was superior to once-daily oral FTC/TDF in ...
JULY 24, 2024
